/
Oncology
Metastatic Castration-Resistant Prostate Cancer
40
Pipeline Programs↗
71
Active Trials↗
27
Companies Involved↗
Metastatic Castration-Resistant Prostate Cancer is a moderately active landscape with 40 programs across 27 companies. The most active players are Bristol-Myers Squibb, K36 Therapeutics, Inc., Bayer. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 111
Phase 28
Phase 34
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
26 of 31 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 80% of 40 pipeline programs.
Analysis
Trial Status
79
clinical trials
Recruiting44 · 56%
Active, not recruiting21 · 27%
Not yet recruiting5 · 6%
Terminated4 · 5%
Completed4 · 5%
Enrolling by invitation1 · 1%
Clinical Trials
Trial Activity
79 trials
A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06922318·50 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)